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Relationships between tumour response and primary tumour
location, and predictors of long-term survival, in patients with
RAS wild-type metastatic colorectal cancer receiving ﬁrst-line
panitumumab therapy: retrospective analyses of the PRIME
and PEAK clinical trials
Marc Peeters1, Timothy Price1,2, Julien Taieb3, Michael Geissler4, Fernando Rivera5, Jean-Luc Canon6, George Pentheroudakis7,
Reija Koukakis8, Peter Burdon9 and Salvatore Siena10
BACKGROUND: Data from two trials of panitumumab in metastatic colorectal cancer (mCRC) were retrospectively analysed to
investigate the effects of primary tumour location on early-tumour shrinkage (ETS) and depth of response (DpR), and identify
factors predicting long-term survival.
METHODS: Patients with RAS wild-type mCRC from PRIME (NCT00364013) and PEAK (NCT00819780) were included. ETS was
deﬁned as a ≥30% reduction in the sum-of-the-longest-diameters of measurable target lesions at eight weeks. DpR was the
maximum percentage change from baseline to nadir in patients with shrinkage. Univariate and multivariate logistic analyses of
short- versus long-term survivor data were performed.
RESULTS: A total of 435/559 (78%) patients had left-sided disease. Of these, a higher proportion of patients treated with
panitumumab versus comparator achieved ETS (PRIME: 62% vs. 36%; PEAK: 58% vs. 41%); median DpR was also higher with
panitumumab (PRIME: 59% vs. 49%; PEAK: 70% vs. 48%). In pooled analyses of the studies, more patients with right-sided disease
achieved ETS if treated with panitumumab than comparator (39% vs. 29%). Panitumumab treatment consistently predicted long-
term survival.
CONCLUSIONS: First-line panitumumab was associated with improved ETS and DpR vs. comparator in patients with left-sided
mCRC. ETS may identify a subgroup of patients with right-sided disease who might respond to panitumumab.
British Journal of Cancer (2018) 119:303–312; https://doi.org/10.1038/s41416-018-0165-z
INTRODUCTION
Colorectal cancer (CRC) is one of the leading causes of cancer
deaths worldwide.1 Almost 50% of patients with CRC develop
metastatic disease, with 25% possessing distant metastases at the
time of diagnosis.2 Systemic treatments for metastatic CRC (mCRC)
include conventional ﬂuoropyrimidine-based chemotherapy and
biological agents that target vascular angiogenesis or the
epidermal growth factor receptor (EGFR).3,4 The latter group of
targeted agents include the anti-EGFR monoclonal antibodies
panitumumab and cetuximab. Patients whose tumours harbour
mutations in RAS do not respond to EGFR-targeted agents, and
may in fact experience inferior outcomes if such agents are
combined with oxaliplatin-containing chemotherapy regimens.4–6
It is therefore essential that before anti-EGFR therapy is initiated in
a patient with mCRC, RAS wild-type (WT) status is conﬁrmed.3,4
V600E BRAF mutations—present in ~10% of CRC tumours—are a
negative prognostic marker in patients with mCRC, although
current evidence on whether these mutations are predictive of the
response to anti-EGFR agents is inconclusive.3,4,7–9 Furthermore,
unlike RAS, extended (non-V600E) BRAF mutations may not have
the same clinical implications.10 Additional biomarkers that may
impact on the response to EGFR-targeted therapies, but remain to
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be conﬁrmed, include human epidermal growth factor (HER) 2 and
3 and MET gene ampliﬁcation.4,11–13 For example, studies have
indicated that HER2 activation substitutes for EGFR dependence in
a subset of mCRC patients, and is therefore a potential negative
predictor of beneﬁt to anti-EGFR therapy.12
Another factor known to affect prognosis and treatment
outcomes in mCRC is primary tumour location. Right-sided
tumours are less prevalent and associated with a poorer prognosis
than left-sided tumours.14–17 Right-sided tumours are also more
frequently associated with mutations in BRAF, TGFβR2 and
PI3KCA.18,19 In contrast, ampliﬁcation of EGFR and HER2, over-
expression of EGFR ligands and chromosomal instability are more
common in left- than right-sided tumours.18–20 According to the
CRC Subtyping Consortium, right-sided tumours are more likely to
be consensus molecular subtype 1 (CMS1), while left-sided
tumours are predominantly CMS2.21
In exploratory analyses of two randomised controlled trials,
PEAK and PRIME, tumour location was found to inﬂuence
outcomes following treatment with the anti-EGFR monoclonal
antibody, panitumumab.14 In the phase II PEAK study, patients
with RAS WT left-sided disease treated with panitumumab plus
modiﬁed (m)FOLFOX6 had numerically longer median PFS and
median overall survival (OS) than patients treated with bevacizu-
mab plus mFOLFOX6 (PFS: 14.6 vs. 11.5 months; OS: 43.4 vs.
32.0 months). In the larger phase III PRIME study, panitumumab
plus FOLFOX4 signiﬁcantly increased median PFS and median OS
vs. FOLFOX4 alone in RAS WT patients with left-sided tumours
(PFS: 12.9 vs. 9.2 months; OS: 30.3 vs. 23.6 months). For patients
with right-sided tumours, however, no statistically signiﬁcant
differences in PFS or OS between panitumumab and the
comparator arms were observed in either PRIME or PEAK,
although no deﬁnitive conclusions could be drawn due to the
relatively low number of these patients.14 In both trials, response
rates were higher in the panitumumab arm vs. the comparator
arm for both left- and right-sided RAS WT tumours. Analyses of
other panitumumab studies showed that patients with RAS WT
left-sided mCRC also beneﬁt when this agent is provided as a
second-line treatment. Meta-analyses of randomised controlled
trials in mCRC have shown improved OS and PFS in RAS WT
patients with left-sided tumours—but not in those with right-
sided tumours—who were treated with EGFR-targeted antibodies
plus chemotherapy, relative to chemotherapy alone or che-
motherapy plus bevacizumab.22,23 In the same meta-analyses,
however, numerical increases in ORR were observed in patients
with right-sided tumours who received anti-EGFR treatment (as
well as in those with left-sided tumours).22,23 These ORR ﬁndings
indicate that doublet chemotherapy plus anti-EGFR therapy
remains an option for patients with right-sided tumours in whom
cytoreduction is the goal.
Here we report additional analyses of the PRIME and PEAK
studies. The ﬁrst set of these analyses were performed to further
characterise the effect of primary tumour location and panitumu-
mab treatment on previously untreated patients with RAS WT
mCRC. Two newer measures of tumour response were considered:
early-tumour shrinkage (ETS) and depth of response (DpR). Used
increasingly in studies of mCRC, ETS and DpR provide information
on tumour shrinkage beyond that provided by the more
traditional Response Evaluation Criteria In Solid Tumors (RECIST).24
ETS may also offer an early indication of sensitivity to
treatment,25,26 while DpR reveals the maximum tumour shrinkage
achieved.27 To date, there are limited data on these response
assessments according to primary tumour location. The second set
of analyses reported here were performed to build upon previous
ﬁndings that primary tumour location inﬂuences outcomes in the
ﬁrst-line setting. Speciﬁcally, we aimed to identify other patient or
disease characteristics that may predict good outcomes (long-
term survival) in patients with mCRC. To do this, we pooled data
across treatment arms from PRIME and PEAK and compared
characteristics between patients with, and those without, very
extended survival. Preliminary results of these analyses have
previously been presented in abstract form.28,29
METHODS
Study designs
Both PRIME and PEAK were randomised controlled trials that
recruited patients with previously untreated mCRC. PRIME
(ClinicalTrials.gov identiﬁer: NCT00364013) was a phase III study
that compared the efﬁcacy and safety of panitumumab 6mg/kg
every two weeks (Q2W) plus FOLFOX4 with FOLFOX4 alone.30
PEAK (NCT00819780) was a phase II study of mFOLFOX6
combined with panitumumab 6mg/kg Q2W or bevacizumab 5
mg/kg Q2W.31 The current analyses focused on RAS WT mCRC and
therefore only included data from patients whose tumours
contained no mutations in KRAS or NRAS exons 2 (codons 12/
13), 3 (codons 59/61) and 4 (codons 117/146). Patients were
characterised as having BRAF mutations if mutations in BRAF exon
15 (at codon 600) were found. All procedures in PRIME and PEAK
were carried out in accordance with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards, and
with the ethical standards of the relevant institutional and/or
national research committees. Signed informed consent was
obtained from all patients. Separate consent was not required
for these retrospective analyses.
Analyses
Impact of primary tumour location on outcomes. Information on
primary tumour location was obtained from free-text surgery
descriptions that were included in case report forms, and from
original pathology reports. Primary tumours located in the caecum
to transverse colon were coded as right-sided, while tumours
located from the splenic ﬂexure to rectum were considered left-
sided. Baseline patient demographics and disease characteristics,
duration of study drug exposure and post-progression (i.e. post-
study) anti-cancer therapy were summarised by study, study
treatment and primary tumour location. The effects of primary
tumour location on ETS and DpR were retrospectively assessed in
each study and in pooled analyses of the two studies. ETS was
deﬁned as a reduction of ≥30% in the sum-of-the-longest-
diameters of measurable target lesions at eight weeks after
initiation of study treatment. A cut-off of ≥30% was selected as
this is in line with RECIST criteria and has been associated with a
similar pattern of beneﬁt as a ≥20% cut-off.24 DpR was calculated
as the maximum percentage change from baseline to nadir in
patients with tumour shrinkage. In patients with tumour growth or
no change in tumour size, DpR was deﬁned as the percentage
change from baseline to progression if the patient subsequently
progressed, or as ‘missing’ if the patient did not progress. Thus,
DpR was positive if there was shrinkage, negative if there was
growth and zero if there was no change. Other outcomes assessed
in the single study and/or pooled analyses were PFS, OS, objective
response rate and resection rate. A Cox proportional hazard model
was used to calculate hazard ratios (HRs) and 95% conﬁdence
intervals (CI) for PFS, OS and ETS. Signiﬁcance was determined
using the Wilcoxon rank-sum test. The Kaplan–Meier method was
used to analyse PFS and OS by treatment, primary tumour location
and ETS status.
Characteristics and response outcomes of long-term survivors.
Long-term survivors were identiﬁed using two different deﬁni-
tions: patients with OS ≥45 months or the 25% of patients with the
longest OS. Given that OS in mCRC is reported to be ≥30 months,
45 months was chosen as a reasonable cut-off for long-term
survival.32,33 For validation, the 25% of patients with the longest
OS were also analysed. Baseline demographic and disease
characteristics, study exposure and outcomes of ﬁrst-line therapy
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were summarised for each study. Based on the work of Köhne and
colleagues,34 patients were retrospectively assigned a baseline
prognostic score (‘Köhne score’) that classiﬁed subjects into high-,
medium- and low-risk groups based on four baseline clinical
parameters: Eastern Cooperative Oncology Group (ECOG) perfor-
mance status, white blood cell count, alkaline phosphatase level
and number of metastatic sites. ETS and DpR were also assessed,
deﬁned as above. Univariate logistic analyses were performed to
descriptively assess the potential relationship of different covari-
ates with long-term survival. The covariates included were sites of
metastases, sex, treatment, ECOG performance status, BRAF status,
primary tumour location, prior adjuvant chemotherapy, country,
age, Köhne score and disease stage. A multivariate logistic analysis
was then conducted using a stepwise model-building procedure
with a 10% signiﬁcance level for a covariate to enter or remain in
the model. Patients who were censored before the cut-off date for
the long-term survivor analyses were excluded from these
analyses as it was not known if such patients were long- or
short-term survivors (by either deﬁnition of long-term survival).
RESULTS
Impact of primary tumour location on outcomes
Patients, study drug exposure and post-progression anti-cancer
therapy. As previously reported,14 there were 675 patients in the
RAS WT populations of PRIME and PEAK. Among the 559 patients
for whom primary tumour location could be determined, 435
(78%) had left-sided tumours and a lower proportion, 124 (22%),
had right-sided tumours, reﬂective of the typical distribution in
RAS WT populations. In both studies, patient demographics and
disease characteristics at baseline were generally similar between
patients with left- and right-sided disease, although those with
right-sided disease were more likely to have BRAF mutations
(Table 1). In PRIME but not PEAK, right-sided disease was more
frequent in females than in males.
More patients with left-sided tumours than right-sided tumours
received study drug for at least nine months. This was the case in
both PRIME and PEAK (Table 1) and when data were pooled across
the two studies (159/435 (37%) vs. 33/124 (27%), respectively).
Post-progression anti-cancer therapy was received by a greater
proportion of patients with left-sided than right-sided disease
(PRIME: 246/328 (75%) vs. 53/88 (60%); PEAK: 83/107 (78%) vs. 23/
36 (64%)). In general, a similar trend was observed for each of the
different treatments that were provided after progression (Table 1).
Among patients treated with panitumumab, those with left-sided
disease were more likely to receive post-progression anti-EGFR
therapy than those with right-sided disease in both PRIME and
PEAK. In contrast, among patients treated with comparator
(FOLFOX4 alone in PRIME; mFOLFOX6 plus bevacizumab in PEAK),
there were no differences in the proportion of patients with left-
vs. right-sided disease who received post-progression anti-EGFR
therapy (Table 1).
Outcomes—single study analyses. Table 2 shows, for PRIME and
PEAK, the effects of panitumumab and comparator treatment on
patient outcomes—including ETS and DpR—by primary tumour
location. In patients with left-sided disease, ETS was achieved in a
higher proportion of those who received panitumumab than
those who received comparator (PRIME 62% vs. 36%; PEAK: 58%
vs. 41%). In patients with right-sided disease, a similar proportion
achieved ETS with panitumumab and comparator in PRIME (31%
in both treatment arms). In PEAK, however, a greater proportion of
these patients experienced ETS with panitumumab than with
comparator (55% vs. 21%). For patients with left-sided tumours,
median DpR was higher with panitumumab than with comparator
(PRIME: 59% vs. 49%, PEAK: 70% vs. 48%). The effects of treatment
on DpR were less clear in patients with right-sided disease (PRIME:
37% vs. 50%; PEAK: 50% vs. 45%). In both studies, more patients
with left- than right-sided disease underwent any resection and
complete (R0) resection (Table 2).
Outcomes–pooled analyses of PRIME and PEAK. In pooled analyses
of PRIME and PEAK, panitumumab improved PFS in patients with
left-sided disease compared with comparator treatment (HR: 0.70,
95% CI: 0.58–0.86). OS was also improved with panitumumab vs.
comparator in patients with left-sided disease (HR: 0.71, 95% CI:
0.57–0.89; Fig. 1a). In patients with right-sided disease, the effects
of panitumumab on PFS and OS relative to comparator were less
clear (HR for PFS: 0.84, 95% CI: 0.58–1.23; HR for OS: 0.90, 95% CI:
0.61–1.32).
In a pooled analysis of both studies and all treatment arms,
more patients with left- vs. right-sided disease experienced ETS
(214/435 (49%) vs. 42/124 (34%)). In total, 39% (24/61) of patients
with right-sided tumours who received panitumumab experi-
enced ETS. In these patients, median PFS was 10.9 months (95%
CI: 9.0–15.8) and median OS was 26.6 months (95% CI: 10.4–36.9).
Among patients with right-sided disease who received compara-
tor treatment, 29% (18/63) had ETS; these patients had a median
PFS of 9.4 months (95% CI: 6.2–16.6) and median OS of
23.6 months (95% CI: 9.8–34.5). Pooled analysis across studies
and treatments showed that ETS was associated with improved
PFS compared with ETS <30%, irrespective of primary tumour
location (HR in left-sided disease: 0.57, 95% CI: 0.46–0.70; HR in
right-sided disease: 0.60, 95% CI: 0.39–0.91). Similar results were
seen for the impact of ETS on OS (HR in left-sided disease: 0.48,
95% CI: 0.38–0.60; HR in right-sided disease: 0.58, 95% CI:
0.38–0.89; Fig. 1b). Across both studies and all treatments, more
patients with left- than right-sided disease underwent any
resection (65/435 (15%) vs. 12/124 (10%)) or complete (R0)
resection (48/435 (11%) vs. 5/124 (4%)).
Characteristics and response outcomes of long-term survivors
Patients. A total of 612 patients were included in the long-term
survivor analysis. Baseline demographics and disease character-
istics for long- and short-term survivors (deﬁned using the 45-
month or 25% cut-offs) are shown for each study in Supplemen-
tary Table 1. In both studies, long-term survivors deﬁned using the
45-month cut-off were more likely than short-term survivors to
have been treated with panitumumab, have an ECOG perfor-
mance status of 0, have BRAF WT mCRC, have left-sided primary
disease and have liver-only metastases. Similar trends were
observed when long-term survival was deﬁned using the 25%
cut-off (Supplementary Table 1).
Outcomes during ﬁrst-line therapy in long-term survivors.
Responses of long- and short-term survivors (deﬁned according
to both cut-offs) are summarised in Table 3. Using the 25% cut-off,
median OS irrespective of treatment arm was 39.5 months in
PRIME (120/475 patients) and 45.9 months in PEAK (34/137
patients). The 25% of patients with the highest OS were more
likely, compared with short-term survivors, to have received study
treatment for at least 9 months, achieved an objective complete
or partial response, undergone any or complete resection, and
experienced ETS (Table 3). These results were driven by those
patients with left-sided tumours (Supplementary Table 2). Median
DpR was also higher in these long-term survivors. Across PRIME
and PEAK, 124 patients (21%) survived for ≥45 months (Table 3). In
pooled analysis of the studies using the 45-month cut-off, median
DpR was 79% (interquartile range: 61–100) in long-term survivors
and 44% (22–61) in short-term survivors, with 68% (84/124) and
37% (175/478) of patients, respectively, experiencing ETS.
The covariates included in the descriptive univariate analysis,
and the results of this analysis when the 45-month cut-off was
used, are shown in Supplementary Table 3. In multivariate
analyses, panitumumab treatment (vs. comparator) was the only
factor that signiﬁcantly predicted long-term survival in both PRIME
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and PEAK according to both the 45-month cut-off (Table 4) and
the 25% cut-off (data not shown). In PRIME, medium-risk Köhne
score, liver-only metastases, ECOG performance status 0 (25% cut-
off only), BRAF WT status, study location in Western Europe,
Canada or Australia (45-month cut-off only), age < 65 years (45-
month cut-off only) and stage I disease (45-month cut-off only)
were also signiﬁcantly associated with long-term survival. In PEAK,
female sex, left-sided primary tumour location, ECOG performance
status 0 and prior adjuvant chemotherapy were associated with
long-term survival (in addition to panitumumab treatment). In
pooled multivariate analyses of PRIME and PEAK using the 45-
month cut-off, panitumumab treatment again predicted long-
term survival, along with low- and medium-risk Köhne score, BRAF
WT status and left-sided primary tumour location (Table 4).
DISCUSSION
We performed two new sets of retrospective analyses of PRIME
and PEAK, two randomised controlled trials that recruited patients
with previously untreated RAS WT mCRC. The main aim of the ﬁrst
set of analyses was to characterise the effects of primary tumour
location and panitumumab treatment on patient outcomes in the
Table 1. Baseline patient demographics and disease characteristics, study drug exposure and post-progression anti-cancer therapy by treatment and
primary tumour location in PRIME and PEAK
PRIME PEAK
Panitumumab+ FOLFOX4 FOLFOX4 Panitumumab+
mFOLFOX6
Bevacizumab+
mFOLFOX6
Left
(n= 169)
Right
(n= 39)
Left
(n= 159)
Right
(n= 49)
Left
(n= 53)
Right
(n= 22)
Left
(n= 54)
Right
(n= 14)
Baseline demographics/disease characteristics
Median age (range), years 61 (27–81) 62 (42–80) 62 (27–82) 61 (24–78) 60 (23–77) 64 (43–82) 60 (39–82) 66 (50–78)
Sex, n (%)
Male 120 (71) 21 (54) 103 (65) 25 (51) 34 (64) 15 (68) 38 (70) 10 (71)
Female 49 (29) 18 (46) 56 (35) 24 (49) 19 (36) 7 (32) 16 (30) 4 (29)
BRAF statusa,b, n (%)
Mutant 7 (4) 13 (33) 8 (5) 16 (33) 1 (2) 9 (41) 1 (2) 1 (7)
Wild-type 156 (92) 26 (67) 148 (93) 32 (65) 52 (98) 13 (59) 53 (98) 13 (93)
Site of metastases, n (%)
Liver+ other 119 (70) 21 (54) 108 (68) 35 (71) 21 (40) 13 (59) 21 (39) 9 (64)
Liver only 33 (20) 6 (15) 31 (19) 5 (10) 18 (34) 4 (18) 15 (28) 4 (29)
Other only 17 (10) 12 (31) 20 (13) 9 (18) 14 (26) 5 (23) 18 (33) 1 (7)
ECOG performance statusa, n (%)
0 106 (63) 22 (56) 88 (55) 27 (55) 37 (70) 10 (45) 35 (65) 9 (64)
1 56 (33) 15 (38) 61 (38) 19 (39) 16 (30) 12 (55) 19 (35) 5 (36)
2 7 (4) 2 (5) 9 (6) 3 (6) 0 0 0 0
Stage IV disease at diagnosis,
n (%)
101 (60) 21 (54) 90 (57) 23 (47) 28 (53) 14 (64) 27 (50) 10 (71)
Prior adjuvant chemotherapy,
n (%)
29 (17) 10 (26) 26 (16) 10 (20) 8 (15) 4 (18) 13 (24) 4 (29)
Study drug exposure and post-progression anti-cancer therapy
First-line study drug exposure, n (%)
<3 months 20 (12) 9 (23) 23 (14) 12 (24) 5 (9) 3 (14) 11 (20) 5 (36)
≥3 to <6 months 45 (27) 13 (33) 48 (30) 16 (33) 13 (25) 7 (32) 13 (24) 1 (7)
≥6 to <9 months 33 (20) 5 (13) 44 (28) 11 (22) 10 (19) 6 (27) 11 (20) 3 (21)
≥9 months 71 (42) 12 (31) 44 (28) 10 (20) 25 (47) 6 (27) 19 (35) 5 (36)
Any post-PD anti-cancer
therapyc, n (%)
126 (75) 21 (54) 120 (75) 32 (65) 39 (74) 14 (64) 44 (81) 9 (64)
Any post-PD anti-EGFR mAb 31 (18) 3 (8) 42 (26) 13 (27) 18 (34) 5 (23) 27 (50) 7 (50)
Small molecule EGFRi 1 (1) 0 4 (3) 0 0 1 (5) 0 0
Any post-PD anti-VEGF
therapy
35 (21) 7 (18) 32 (20) 10 (20) 28 (53) 10 (45) 23 (43) 4 (29)
Fluoropyrimidine 97 (57) 17 (44) 89 (56) 22 (45) 37 (70) 13 (59) 34 (63) 4 (29)
Irinotecan 94 (56) 17 (44) 97 (61) 29 (59) 34 (64) 10 (45) 36 (67) 7 (50)
Oxaliplatin 35 (21) 6 (15) 25 (16) 6 (12) 13 (25) 1 (5) 13 (24) 3 (21)
Other/unknown 74 (44) 12 (31) 62 (39) 17 (35) 31 (58) 10 (45) 41 (76) 4 (29)
ECOG Eastern Cooperative Oncology Group, EGFR(i) epidermal growth factor receptor (inhibitor), mAb monoclonal antibody, mFOLFOX6 modiﬁed FOLFOX6, PD
progressive disease, VEGF vascular endothelial growth factor. aUnknown for some patients. bPatients were characterised as having BRAF mutations if mutations
in BRAF exon 15 (at codon 600) were found. cPatients could have ≥1 post-PD therapy
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ﬁrst-line setting, beyond those already reported.14 For patients
with left-sided disease, our analyses suggest that in addition to its
known beneﬁcial effects on OS, PFS and other ‘traditional’
endpoints in this population, panitumumab may also improve
outcomes relative to comparator treatment as measured by two
newer endpoints, ETS and DpR. The data were less conclusive for
patients with right-sided disease but suggest that ETS may identify
a subgroup of these patients who might respond to panitumu-
mab. The second set of analyses, which aimed to identify other
patient or disease characteristics that may predict a favourable
prognosis in patients with mCRC, found that panitumumab
treatment was the only factor that signiﬁcantly predicted long-
term survival in both trials.
Regarding the ﬁrst set of analyses, individual assessments of
PRIME and PEAK revealed that a higher proportion of patients with
left-sided disease achieved ETS with panitumumab than with
comparator. Median DpR was also higher with panitumumab vs.
comparator in these patients in both studies. ETS, as well as DpR,
provide information on tumour shrinkage over and above that
provided by RECIST, speciﬁcally on the timing, depth and duration
of response. As a result, they are increasingly being utilised as
endpoints in mCRC studies. Achieving early and sustained tumour
shrinkage is an important treatment goal in patients with mCRC as
it may increase the chance of surgical resection, reduce
chemotherapy-associated liver toxicity prior to resection and
provide relief of tumour-related symptoms.26,35 That our pooled
analysis of PRIME and PEAK showed superior survival outcomes
with panitumumab vs. comparator in patients with left-sided
disease was consistent with other reports.15–17 Overall, our
ﬁndings in patients with previously untreated left-sided RAS WT
tumours further conﬁrm that anti-EGFR therapy is an appropriate
choice for this population. However, the beneﬁts of panitumumab
treatment in the PEAK and PRIME studies were less evident in
patients with right-sided disease, with DpR, OS and PFS ﬁndings,
for example, being much less clear in this population. These results
are consistent with past reports of an unclear beneﬁt of anti-EGFR
therapy in patients with RAS WT right-sided mCRC.14,16,22,23 Of
note, however, objective response rates for right-sided disease
have previously been shown to be higher for panitumumab vs.
bevacizumab.14,22 Moreover, addition of panitumumab to FOLFOX-
IRI in the randomised phase II VOLFI trial resulted in high response
rates in left- and right-sided RAS WT mCRC.36 It seems pertinent to
ask then if there is a subgroup of patients with right-sided disease
who should be considered for anti-EGFR therapy and, if so, how
they can be identiﬁed. With these questions in mind, it is of interest
that across the two studies reported here, patients with right-sided
disease were more likely to achieve ETS if they were treated with
panitumumab than with comparator. Median PFS and OS in
patients with right-sided disease who achieved ETS were also
numerically longer with panitumumab than with comparator.
While intrinsic tumour sensitivity to therapy remains the main
determinant of clinical outcome, ETS might therefore identify a
subgroup of patients with right-sided disease who may achieve
improved outcomes with panitumumab and who may therefore
beneﬁt from further treatment. Additional research is needed to
help physicians identify such patients in the clinic, including those
with bulky tumours and those who can be converted from non-
resectable to resectable disease. The optimal treatment approach
for these and other mCRC patients also needs to be better deﬁned;
for example, with respect to which treatment sequences may be
best for different patients. For RAS WT patients, accumulating
evidence supports the use of ﬁrst-line anti-EGFR treatment,
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followed by anti-VEGF therapy.37,38 In this context, ETS may be
useful in guiding both the decision to switch therapy and the
timing of the switch.
Evidence suggests that converting non-resectable mCRC to
resectable disease leads to better outcomes.39 In the current
analyses, patients with left-sided disease were more likely to
undergo tumour resection than those with right-sided disease. We
also showed that in the panitumumab arms of both PRIME and
PEAK, the incidence of post-progression anti-EGFR therapy was
higher in patients with left- than right-sided disease. This may be
because the former group of patients are more likely to have
shown a good response to ﬁrst-line panitumumab. In patients in
the comparator arms, the incidence of post-progression anti-EGFR
therapy was similar regardless of primary tumour location. The
dynamic susceptibility of mCRC to therapeutic EGFR blockade
means that it may be possible to extend survival by rechallenge
with EGFR inhibitors. Anti-EGFR treatment may select for
treatment-resistant subclones that are present before treatment,
leading to secondary resistance of the tumour.40 Removing anti-
EGFR selection pressure, via a break in anti-EGFR treatment, may
allow sensitive clones to become re-established, restoring tumour
sensitivity.41–43 Rechallenge after a break from EGFR inhibitor
treatment may thus be a viable strategy for later lines of treatment
in patients with a good initial response.44,45 As an early indication
of patients who are responding to treatment, ETS might therefore
help identify patients suitable for rechallenge. Prospective
controlled trials testing rechallenge, and attempting to identify
biopsy biomarkers that can predict its efﬁcacy, as well as the
mechanisms underlying ﬂuctuating tumour sensitivity to
treatment, are currently ongoing, including A-REPEAT
(NCT03311750), CHRONOS (NCT03227926) and RASINTRO
(NCT03259009).
The second set of analyses reported here aimed to identify
clinicopathologic characteristics beyond primary tumour loca-
tion that may predict a favourable prognosis in patients with
RAS WT mCRC. These analyses used ‘long-term survival’ as an
indicator of good prognosis, deﬁned as either patients with OS
of at least 45 months (equivalent to 19% of patients in PRIME
and 25% of patients in PEAK) or the 25% of patients with the
longest OS. Applying either of these deﬁnitions of long-term
survival in multivariate analyses, panitumumab treatment was
the only factor that signiﬁcantly predicted long-term survival in
both the PRIME and the PEAK trials (and in a pooled analysis of
both). Other characteristics that signiﬁcantly predicted long-
term survival in either PRIME or PEAK or both trials combined
included baseline disease characteristics associated with favour-
able prognosis (e.g. low- or medium-risk Köhne score, liver-only
metastases, ECOG performance status of 0, BRAF WT status), and
left-sided disease. Some characteristics could not be modelled in
the multivariate analyses due to imbalances across the
subgroups, as revealed by univariate analyses. Compared with
short-term survivors, long-term survivors more frequently
experienced an objective response or ETS, were more likely to
have had a resection and had a greater DpR. To our knowledge
this is the ﬁrst reported analysis to compare characteristics of
long- and short-term survivors among a cohort of mCRC patients
treated with anti-EGFR therapy. Of note, however, ETS has been
shown to be associated with longer PFS and OS in patients with
Table 3. Response to ﬁrst-line therapy in long- and short-term survivors in PRIME and PEAK
Characteristic 25% survival cut-offa 45-month cut-offb
PRIME PEAK PRIME PEAK
Long-term
survivor
(n= 120)
Short-term
survivor
(n= 355)
Long-term
survivor
(n= 34)
Short-term
survivor
(n= 103)
Long-term
survivor
(n= 89)
Short-term
survivor
(n= 375)
Long-term
survivor
(n= 35)
Short-term
survivor
(n= 103)
Exposure duration, n (%)
<3 months 5 (4) 72 (20) 4 (12) 15 (15) 5 (6) 72 (19) 4 (11) 15 (15)
≥3 to <6 months 21 (18) 110 (31) 6 (18) 28 (27) 14 (16) 113 (30) 6 (17) 28 (27)
≥6 to <9 months 27 (23) 83 (23) 7 (21) 23 (22) 21 (24) 86 (23) 8 (23) 23 (22)
≥9 months 67 (56) 90 (25) 17 (50) 37 (36) 49 (55) 104 (28) 17 (49) 37 (36)
Resection, n (%)
Any 36 (30) 21 (6) 9 (26) 3 (3) 29 (33) 22 (6) 10 (29) 3 (3)
Complete 29 (24) 9 (3) 6 (18) 3 (3) 23 (26) 10 (3) 6 (17) 3 (3)
Best overall response, n (%)
Complete response 0 2 (1) 5 (15) 0 0 2 (1) 5 (14) 0
Partial response 89 (74) 160 (45) 24 (71) 59 (57) 67 (75) 174 (46) 24 (69) 59 (57)
Stable disease 25 (21) 136 (38) 5 (15) 32 (31) 16 (18) 142 (38) 6 (17) 32 (31)
Progressive disease 4 (3) 44 (12) 0 5 (5) 4 (4) 44 (12) 0 5 (5)
Not known/
unavailable
2 (2) 13 (4) 0 7 (7) 2 (2) 13 (3) 0 7 (7)
ETS, n (%) 77 (64) 123 (35) 26 (76) 42 (41) 58 (65) 133 (35) 26 (74) 42 (41)
Median DpR (IQR), % 75 (60–89) 43 (18–59) 86 (61–100) 45 (26–60) 77 (61–96) 44 (19–62) 87 (61–100) 45 (26–60)
Received post-
progression EGFRi
therapy, n (%)
44 (37) 62 (17) 16 (47) 40 (39) 30 (34) 71 (19) 17 (49) 40 (39)
DpR depth of response, EGFRi epidermal growth factor receptor inhibitor, ETS early-tumour shrinkage, IQR interquartile range, OS overall survival. aLong-term
survival deﬁned as the 25% of classiﬁable patients with the longest OS (this included some patients that survived less than 45 months); all other patients were
deﬁned as short-term survivors. bLong-term survival deﬁned as OS ≥45 months; short-term survival deﬁned as OS <45 months
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RAS WT mCRC treated with cetuximab.25 Further to this, a
retrospective analysis of three trials in RAS WT mCRC patients
found that ETS and DpR were associated with improved
survival.24 However, these studies were not designed to
compare long- and short-term survivors.
The analyses reported here have provided further insights into
the impact of primary tumour location and panitumumab
treatment on outcomes in PRIME and PEAK, and on factors
beyond left-sided disease that may predict a good prognosis in
patients with RAS WT mCRC. A limitation of our analyses is that
they were post-hoc and unplanned. With respect to ETS and DpR
speciﬁcally, these endpoints were not in use when the trials were
designed ~10 years ago, and thus they were not included as pre-
speciﬁed endpoints in the trial protocols. ETS and DpR are now,
however, used increasingly in mCRC as early indicators of
treatment efﬁcacy.25–27 A further limitation is that differences in
OS were observed between the full study populations of PRIME
and PEAK, which may reﬂect differences in patient characteristics
between the two studies (and/or greater data variability in smaller
studies such as PEAK or differences in treatment sequencing or
use of anti-angiogenic (bevacizumab) therapy). In this respect and
due to the differences in trial methodology and the number of
patients recruited to each trial, pooled data should be cautiously
interpreted. In addition, some patients in the full study popula-
tions were omitted from these analyses since data on, for
example, tumour mutation status or primary tumour location
were not available, or in the case of the long-term survivor
analyses, because survival data were censored before the cut-off
date. Finally, some of the subgroups analysed, especially those
deriving from the PEAK trial and those containing patients with
right-sided disease, contained very small numbers of patients that
may have impacted on validity of these analyses.
In conclusion, the additional analyses of PRIME and PEAK
reported here have shown that ﬁrst-line panitumumab plus
chemotherapy resulted in a higher rate of ETS and a higher DpR
compared with ﬁrst-line chemotherapy (with or without bevaci-
zumab) in RAS WT patients with left-sided primary tumours.
Pooled analyses also conﬁrmed that panitumumab improved
survival outcomes, including PFS and OS, vs. comparator in these
patients. In patients with right-sided disease, data were difﬁcult to
interpret due to the low patient numbers in this subgroup, yet
may indicate that ETS could be used to identify a subgroup of
patients with right-sided disease who may achieve improved
outcomes with panitumumab therapy. Panitumumab treatment
signiﬁcantly predicted long-term survival in both PRIME and
PEAK.
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